Building F2
No. 88 Kechuang 6th Street Beijing Economic-Technological Development Area
Beijing
China
86 10 5631 5466
https://www.jacobiopharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 301
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Yinxiang Wang | Executive Chairman & CEO | 3.43M | 無 | 1965 |
Ms. Xiaojie Wang | Executive Director & President of Administration | 2.56M | 無 | 1965 |
Ms. Yunyan Hu | Executive VP & Executive Director | 2.56M | 無 | 1962 |
Ms. Tao Yang | Vice President of Human Resources | 無 | 無 | 無 |
Dr. Andrea Wang-Gillam M.D., Ph.D. | Executive VP, Chief Medical Officer and Global Head of R&D | 無 | 無 | 1971 |
Ms. Yanping Wang | Executive Vice President of Non-Clinical R&D | 無 | 無 | 無 |
Dr. Haijun Wang | Senior Vice President of Information & Data Management | 無 | 無 | 無 |
Dr. Wei Long | Head of Drug Discovery | 無 | 無 | 無 |
Ms. Yuli Ding | Executive Vice President of Clinical Development | 無 | 無 | 無 |
Ms. Qing Xue | Joint Company Secretary | 無 | 無 | 1989 |
Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.
截至 無 止,加科思-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。